These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

868 related items for PubMed ID: 25788382

  • 21. Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
    Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, Schlichting P, Orholm M, Ring-Larsen H, Bukh J, Krogsgaard K.
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1115-9. PubMed ID: 22670704
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
    Deltenre P, Corouge M, Canva V, Castel H, Wartel F, Dharancy S, Louvet A, Lazrek M, Moreno C, Henrion J, Mathurin P.
    J Hepatol; 2011 Nov; 55(5):989-95. PubMed ID: 21354445
    [Abstract] [Full Text] [Related]

  • 28. Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.
    Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, Aljudaibi BM.
    Saudi J Gastroenterol; 2013 Nov; 19(5):223-9. PubMed ID: 24045596
    [Abstract] [Full Text] [Related]

  • 29. [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
    Ji F, Dang S, Cai Z, Xue H, Huang N, Liu L, Zhang S, Guo Y, Jia X, Wang Y, Li Z, Deng H.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):647-52. PubMed ID: 26524356
    [Abstract] [Full Text] [Related]

  • 30. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N, Habibi MS, Brown A.
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [Abstract] [Full Text] [Related]

  • 31. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
    Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D'Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G, CLEO Group.
    BMC Gastroenterol; 2012 Nov 16; 12():162. PubMed ID: 23157720
    [Abstract] [Full Text] [Related]

  • 32. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marenco S, Grasso A, Pirisi M, Smirne C, Colletta C, Traverso A, Mazzucco D, Ciccone G, Simondi D, Rizzetto M, Saracco G.
    Eur J Gastroenterol Hepatol; 2014 Jan 16; 26(1):52-8. PubMed ID: 23719564
    [Abstract] [Full Text] [Related]

  • 33. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.
    Eur J Gastroenterol Hepatol; 2013 Jul 16; 25(7):798-805. PubMed ID: 23395996
    [Abstract] [Full Text] [Related]

  • 34. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
    Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.
    J Viral Hepat; 2009 Aug 16; 16(8):578-85. PubMed ID: 19552663
    [Abstract] [Full Text] [Related]

  • 35. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD.
    World J Gastroenterol; 2015 May 28; 21(20):6236-45. PubMed ID: 26034358
    [Abstract] [Full Text] [Related]

  • 36. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    El-Hamamsy M, Montasser IF, Mansy AE, Nabet DE, El-Meteini M.
    J Clin Pharm Ther; 2019 Jun 28; 44(3):447-453. PubMed ID: 30714175
    [Abstract] [Full Text] [Related]

  • 37. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.
    Gastroenterology; 2014 Feb 28; 146(2):442-52.e1. PubMed ID: 24126097
    [Abstract] [Full Text] [Related]

  • 38. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.
    World J Gastroenterol; 2013 May 14; 19(18):2793-8. PubMed ID: 23687416
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
    Transpl Int; 2007 Jul 14; 20(7):583-90. PubMed ID: 17433090
    [Abstract] [Full Text] [Related]

  • 40. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
    Al-Hamoudi W, Mohamed H, Abaalkhail F, Kamel Y, Al-Masri N, Allam N, Alqahtani S, Al-Sofayan M, Khalaf H, Al-Sebayel M, Al-Jedai A, Abdo A.
    Dig Dis Sci; 2011 Jun 14; 56(6):1848-52. PubMed ID: 21221800
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.